Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of defibrotide for the treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Next Previous
Trial Profile

Safety and efficacy of defibrotide for the treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Defibrotide (Primary)
  • Indications Hepatic veno-occlusive disease; Veno-occlusive disorders
  • Focus Therapeutic Use
  • Acronyms DEFIFrance

Most Recent Events

  • 12 Dec 2023 Results of pooled analysis (DEFIFrance and EBMT PASS ), analysing the treatment duration and time to resolution of Veno-occlusive disease/sinusoidal obstruction syndrome in patients given defibrotide for the treatment of severe or nonsevere Veno-occlusive disease/sinusoidal obstruction syndrome post-hematopoietic cell transplantation, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 23 Dec 2022 Status changed from recruiting to completed, according to the results published in the Bone Marrow Transplantation
  • 23 Dec 2022 Results published in the Bone Marrow Transplantation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top